Literature DB >> 26179538

Relapse with Dysphagia in a Case of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Hiroko Teramoto1, Akihiko Morita, Makoto Hara, Satoko Ninomiya, Shuntaro Shigihara, Susumu Kusunoki, Satoshi Kamei.   

Abstract

Glossopharyngeal and/or vagus nerve involvement is infrequent in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). We herein report the case of a 69-year-old Japanese woman who presented with muscle weakness and numbness of the extremities with dysphagia. The serum anti-ganglioside GM1 immunoglobulin IgM antibody levels were elevated, and treatment with intravenous immunoglobulin (IVIg) resulted in a dramatic improvement; the weakness, numbness and dysphagia all resolved. However, relapse comprising dysphagia alone occurred on hospital day 26, and treatment with IVIg again proved extremely effective. IVIg therapy can be effective against cranial nerve involvement in cases of CIDP.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26179538     DOI: 10.2169/internalmedicine.54.4300

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Monocentric study of 28 cases of chronic inflammatory demyelinating polyneuropathy: first Tunisian study.

Authors:  Malek Mansour; Amine Rachdi; Nesrine Baradai; Amel Kacem; Ines Bedoui; Ridha Mrissa
Journal:  Neurol Sci       Date:  2021-05-04       Impact factor: 3.307

2.  An Atypical Phenotype of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Associated with Ocular Palsy, IgM-anti Ganglioside Antibody, and Fever-induced Recurrence.

Authors:  Midori Horiuchi; Yu Hongo; Keishi Yamazaki; Yukari Komuta; Masato Kadoya; Hiroshi Takazaki; Yuichiro Furuya; Taro Matsui; Naohiro Sakamoto; Katsunori Ikewaki; Kazushi Suzuki; Kenichi Kaida
Journal:  Intern Med       Date:  2021-10-05       Impact factor: 1.282

Review 3.  Autoimmune Neurogenic Dysphagia.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Dysphagia       Date:  2021-07-05       Impact factor: 2.733

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.